Less than one month is left before the beginning of the largest annual radiation oncology meeting; ASTRO 2018, which this year will be taking place on the 21st to 24th of October at the Henry B. Gonzalez Convention Center, in San Antonia, Texas. Xstrahl would like to...
According to the American Academy of Dermatology, it is estimated that non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million Americans a year and 178,560 new cases of melanoma, including 91,270 invasive, will...
Combined immune checkpoint blockade has led to rare autoimmune complications, such as fatal myocarditis. Recent approvals of several anti-programmed death 1 (anti-PD-1) drugs for lung cancer treatment prompted ongoing clinical trials that directly combine PD-1...
In many European countries, patients with a variety of chronical inflammatory diseases are treated with low-dose radiotherapy (LD-RT). In contrast to high-dose irradiation given to tumor patients, little is known about radiobiological mechanisms underlying this...
Eat, Sleep, Radiate, Repeat. Xstrahl is delighted to invite you to attend its booth at the 64th Annual Meeting of the Radiation Research Society held at the Historic Hilton Chicago Hotel on September 23-26, 2018, in conjunction with the Conference on Radiation &...
Cancer treatment has come a long way in a short time, however as new drugs and treatments are developed, the therapeutic index of treatments needs to be assessed. In their study “Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in...
Radiotherapy enhances innate and adaptive antitumor immunity; however, the effects of radiation on suppressive immune cells, such as regulatory T cells (Treg), in the tumor microenvironment (TME) are not fully elucidated. Although previous reports suggest an increased...
Sydney Vital, a translational cancer research centre funded by the Cancer Institute New South Wales (CINSW) and the University of Sydney, is the first centre in Australia to acquire an Xstrahl Small Animal Radiation Research Platform (SARRP). Sydney Vital’s aim is to...
Sydney Vital, a translational cancer research centre funded by the Cancer Institute New South Wales (CINSW) and the University of Sydney, is the first centre in Australia to acquire an Xstrahl Small Animal Radiation Research Platform (SARRP). Sydney Vital’s aim is to...